Celcuity (CELC) Q2 2026 Earnings Call Transcript
Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on cash position, loss magnitude, and capital structure, influencing short-term price action and longer-term valuation.
Market read
The announcement combines earnings disappointment with a significant capital raise and regulatory approval, creating a mixed short-term trading signal for the stock.
What to watch
Potential revenue from Revtopik pricing and upcoming VIKTORIA-2 trial data could materially improve outlook.
Background
Celcuity reported its Q2 2026 financial results, highlighted a net loss, a $575M convertible note offering, and FDA approval of its lead product Revtopik.
Ticker impact
Q2 2026 earnings call disclosed a $78.9M net loss, $575M convertible note raise and FDA approval of Revtopik.
Potential near-term downside on earnings miss, followed by stabilization as cash runway and approval are priced in.
Losses and higher SG&A weigh on valuation, but $754M cash and FDA approval are material positive catalysts.
Market effects
Biotech sector may see renewed interest in PI3K/mTOR inhibitors after FDA approval.
U.S. biotech investors may adjust exposure to small-cap pipelines.
Limited to companies developing similar targeted therapies.
Counterpoint
Despite the loss, the cash runway and FDA approval could support a bounce if the market overreacts to the earnings miss.
Key entities
- CompanyCelcuity
Biopharma developing gedatolisib and Revtopik.
- ExecutiveBrian F. Sullivan
CEO and cofounder of Celcuity.